前列腺癌主动监测的演变:磁共振成像、磁共振引导活检与局灶治疗的影响
该研究分析869名接受主动监测(AS)的前列腺癌患者,基线磁共振引导活检(MRGB)显示GG≤2。随访中MRI对无进展的阴性预测值在基线GG0、GG1、GG2中分别近95%、90%、70%,提示常规随访活检或可避免。部分患者接受局灶治疗(FT)后5年无根治性治疗生存率84%,高于未接受FT者的46%(P<.01),FT可能延长AS并推迟手术或放疗。
要点
- 基线MRGB显示GG≤2的患者,MRI随访对无进展的阴性预测值高,常规随访活检或可避免。
- 基线GG0、GG1、GG2患者进展至≥GG3的比例分别为7%、19%、34%。
- 符合条件的患者中25%接受FT,5年无根治性治疗生存率84% vs 46%(P<.01)。
核心结论
- AS的持久性可能与基线MRGB结果相关。
- 以MRGB开始AS的低危前列腺癌患者,后续MRI具有高阴性预测值,提示常规随访活检可避免。
- 部分患者接受FT可能延长AS并推迟手术或放疗。
研究设计与样本
- 加州大学洛杉矶分校AS方案研究(2010-2022)的869名男性队列分析。
- 纳入标准为基线MRGB显示GG≤2且入组≥1年。
- 2016年后,向GG2及进展至GG3的男性提供FT。
主要发现
- 869名男性累计3500患者年随访,中位随访4.1年。
- 基线为GG1者505例、GG2者174例、GG0者190例(GG0指既往诊断GG1或2但基线MRGB阴性)。
- 664名接受系列MRGB者中,进展至≥GG3的比例:GG0为7%、GG1为19%、GG2为34%。
- MRI正确识别无进展的阴性预测值:基线GG0近95%、GG1为90%、GG2为70%。
- 393名符合条件者中99名(25%)接受FT,其5年无根治性前列腺切除/放疗生存率为84%,未接受FT组为46%(P<.01)。
临床怎么用
- 对于以MRGB开始AS的低危前列腺癌患者,可考虑用MRI随访替代常规随访活检。
- 对GG2及进展至GG3的部分患者,FT可能作为延长AS、推迟根治性治疗的选项。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aimed to determine if, using baseline MRI-guided biopsy (MRGB), durability of active surveillance (AS) could be predetermined, follow-up biopsies avoided, and if by incorporating focal therapy (FT), AS extended. MATERIALS AND METHODS: A cohort of 869 men in the University of California, Los Angeles, protocol study of AS (2010-2022) was analyzed. Inclusion criteria were baseline MRGB showing Grade Group (GG) ≤ 2 and ≥ 1 year enrollment. After 2016, FT was offered to men with GG2 and those progressing to GG3. RESULTS: The 869 men accrued 3500 patient-years of follow-up (median follow-up 4.1 years). At baseline, men were GG1 (505), GG2 (174), or "GG0" (190), the latter describing those with prior diagnostic GG1 or 2, but negative baseline MRGB. Overall, progression to ≥ GG3 among the 664 with serial MRGB was 7% for GG0, 19% for GG1, and 34% for GG2. During follow-up, the absence of progression (negative predictive value) was correctly identified by MRI in nearly 95% of men with baseline GG0, 90% of men with GG1, and 70% of men with GG2. FT was performed in 99/393 eligible men (25%); among them, 5-year probability of radical prostatectomy/radiation therapy-free survival was 84% compared with 46% in the no-FT group (P < .01). CONCLUSIONS: Durability of AS may be linked to baseline MRGB. In men starting AS with MRGB and low-risk prostate cancer, subsequent MRI exhibits high negative predictive value, indicating routine follow-up biopsy is avoidable. In some men, FT may allow extension of AS and deferral of surgery or radiation.
引用
- Martin SC, Gonzalez S, Kwan L, et al. Evolution of Active Surveillance of Prostate Cancer: Impact of Magnetic Resonance Imaging, Magnetic Resonance Imaging-Guided Biopsy, and Focal Therapy. J Urol. 2025. PMID: 40257918. doi:10.1097/JU.0000000000004559
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。